Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.
Engelhardt JA, Fant P, Guionaud S, Henry SP, Leach MW, Louden C, Scicchitano MS, Weaver JL, Zabka TS, Frazier KS; Society of Toxicologic Pathology Vascular Injury Working Group. Engelhardt JA, et al. Among authors: zabka ts. Toxicol Pathol. 2015 Oct;43(7):935-44. doi: 10.1177/0192623315570341. Epub 2015 Feb 24. Toxicol Pathol. 2015. PMID: 25717082 Review.
Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.
Mikaelian I, Cameron M, Dalmas DA, Enerson BE, Gonzalez RJ, Guionaud S, Hoffmann PK, King NM, Lawton MP, Scicchitano MS, Smith HW, Thomas RA, Weaver JL, Zabka TS; Vascular Injury Working Group of the Predictive Safety Consortium. Mikaelian I, et al. Among authors: zabka ts. Toxicol Pathol. 2014 Jun;42(4):635-57. doi: 10.1177/0192623314525686. Epub 2014 Apr 28. Toxicol Pathol. 2014. PMID: 24777748
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.
Frazier KS, Engelhardt JA, Fant P, Guionaud S, Henry SP, Leach MW, Louden C, Scicchitano MS, Weaver JL, Zabka TS; Society of Toxicologic Pathology Vascular Injury Working Group. Frazier KS, et al. Among authors: zabka ts. Toxicol Pathol. 2015 Oct;43(7):915-34. doi: 10.1177/0192623315570340. Epub 2015 Feb 26. Toxicol Pathol. 2015. PMID: 25722122 Review.
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Tarrant JM, Dhawan P, Singh J, Zabka TS, Clarke E, DosSantos G, Dragovich PS, Sampath D, Lin T, McCray B, La N, Nguyen T, Kauss A, Dambach D, Misner DL, Diaz D, Uppal H. Tarrant JM, et al. Among authors: zabka ts. Toxicol Mech Methods. 2015 Mar;25(3):201-11. doi: 10.3109/15376516.2015.1014080. Epub 2015 Apr 20. Toxicol Mech Methods. 2015. PMID: 25894564
An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation.
Authier S, Abernathy MM, Correll K, Chui RW, Dalton J, Foley CM, Friedrichs GS, Koerner JE, Kallman MJ, Pannirselvam M, Redfern WS, Urmaliya V, Valentin JP, Wisialowski T, Zabka TS, Pugsley MK. Authier S, et al. Among authors: zabka ts. Int J Toxicol. 2020 Jul/Aug;39(4):274-293. doi: 10.1177/1091581820921338. Epub 2020 May 14. Int J Toxicol. 2020. PMID: 32406289
Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats.
Burch PM, Greg Hall D, Walker EG, Bracken W, Giovanelli R, Goldstein R, Higgs RE, King NM, Lane P, Sauer JM, Michna L, Muniappa N, Pritt ML, Vlasakova K, Watson DE, Wescott D, Zabka TS, Glaab WE. Burch PM, et al. Among authors: zabka ts. Toxicol Sci. 2016 Mar;150(1):247-56. doi: 10.1093/toxsci/kfv328. Epub 2015 Dec 31. Toxicol Sci. 2016. PMID: 26721300
49 results